Novartis says it benefited from the weakness of the US dollar against other major currencies.

The Basel-based company also saw strong sales of newly launched products such as the oral multiple sclerosis medicine Gilenya.

Novartis earned $2.44 billion during the same period last year on sales of $11.72 billion.

The company said Tuesday that sales in the April to June period increased by 19 percent to reach $14.92 billion.